GlassScriptPhysician profile
Philip L Marjon
NPI 1912234121
$22,459.23
in general payments reported to CMS, 2019-2025
87 companies · $5,865 in 2025
The $5,865 reported for 2025 was more than what 84% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $0.51 · 2020: $30.52 · 2021: $221 · 2022: $3,794 · 2023: $6,308 · 2024: $6,240 · 2025: $5,865.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $17K · Long Term Medical Supply Or Device Loan: $798 · Education: $552.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $17,064.03 |
| Long Term Medical Supply Or Device Loan | $797.60 |
| Education | $551.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,548.05 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,868.79 | 2022-2025 | Imfinzi, Lynparza, Datroway |
| Janssen Biotech, INC. | $1,186.77 | 2021-2025 | Darzalex, Tecvayli, Talvey |
| E.R. Squibb & Sons, L.L.C. | $1,138.71 | 2020-2025 | Opdivo, Opdualag, Reblozyl |
| Gilead Sciences, INC. | $988.49 | 2022-2025 | Trodelvy |
| Pfizer INC. | $914.51 | 2022-2025 | |
| Celgene Corporation | $905.18 | 2022-2025 | Reblozyl, Pomalyst, Breyanzi |
| Eisai INC. | $752.21 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $716.03 | 2022-2025 | Libtayo |
| Incyte Corporation | $672.16 | 2022-2025 | Jakafi, Monjuvi |
| Takeda Pharmaceuticals U.S.A., INC. | $644.61 | 2022-2025 | Ninlaro, Alunbrig, Fruzaqla |
| Alexion Pharmaceuticals, INC. | $611.16 | 2022-2025 | Ultomiris |
| Merck Sharp & Dohme LLC | $571.70 | 2022-2025 | Keytruda, Welireg, Lynparza |
| Genzyme Corporation | $570.82 | 2022-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $546.95 | 2021-2023 | Imbruvica, Epkinly |
Show all 87 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $540.41 | 2022-2025 | |
| Mirati Therapeutics, INC. | $425.78 | 2023-2024 | Krazati |
| Daiichi Sankyo INC. | $358.91 | 2022-2025 | Enhertu |
| Karyopharm Therapeutics INC. | $348.72 | 2022-2025 | Xpovio |
| Regeneron Pharmaceuticals, INC. | $278.86 | 2024-2025 | Libtayo |
| Rigel Pharmaceuticals, INC. | $268.57 | 2021-2024 | Rezlidhia, Tavalisse |
| Aveo Pharmaceuticals, INC. | $260.02 | 2022-2025 | |
| Sobi, INC | $259.50 | 2022-2025 | |
| Seagen INC. | $248.72 | 2021-2023 | Adcetris, Padcev, Tukysa |
| Astellas Pharma US INC | $236.43 | 2022-2025 | Xospata, Vyloy, Xtandi |
| Bayer Healthcare Pharmaceuticals INC. | $225.14 | 2022-2025 | |
| Emd Serono, INC. | $218.92 | 2024-2025 | |
| Genentech USA, INC. | $202.89 | 2022-2025 | Polivy, Venclexta, Lunsumio |
| Array Biopharma INC | $199.85 | 2023-2025 | Braftovi, Mektovi, Xalkori |
| Beigene USA, INC. | $175.60 | 2022-2025 | Brukinsa, Tevimbra |
| Blueprint Medicines Corporation | $167.10 | 2022-2025 | Ayvakit |
| Pharmaessentia USA Corporation | $166.20 | 2023-2025 | Besremi |
| Tempus Ai, INC | $161.73 | 2024 | |
| Taiho Oncology, INC. | $159.10 | 2022-2025 | |
| Puma Biotechnology, INC. | $155.54 | 2022-2025 | |
| Exelixis INC. | $135.93 | 2024-2025 | Cabometyx |
| Kite Pharma, INC. | $130.58 | 2022-2024 | Yescarta |
| Epizyme, INC. | $129.80 | 2020-2023 | Tazverik |
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.86 | 2022-2025 | Gilotrif |
| Adaptive Biotechnologies Corporation | $120.79 | 2022-2023 | Clonoseq |
| Foundation Medicine, INC. | $117.91 | 2022-2023 | |
| Sumitomo Pharma America, INC. | $103.10 | 2023-2025 | Orgovyx |
| Dendreon Pharmaceuticals LLC | $97.18 | 2023-2025 | Provenge |
| Ipsen Biopharmaceuticals, INC | $93.92 | 2022-2024 | Somatuline Depot, Onivyde, Tazverik |
| Beone Medicines USA, INC. | $88.75 | 2025 | Brukinsa, Tevimbra |
| Glaxosmithkline, LLC. | $88.43 | 2022-2025 | Ojjaara |
| Deciphera Pharmaceuticals INC. | $85.95 | 2023-2025 | Qinlock, Romvimza |
| Stemline Therapeutics INC. | $75.30 | 2023-2025 | Orserdu |
| Genmab U.S., INC. | $69.62 | 2024-2025 | Epkinly |
| Lilly USA, LLC | $68.90 | 2023-2024 | Jaypirca, Retevmo, Verzenio |
| Tersera Therapeutics LLC | $65.29 | 2022-2023 | Xermelo |
| Novocure INC. | $62.94 | 2022-2024 | Optune |
| Amgen INC. | $54.84 | 2022 | |
| Cti Biopharma Corp. | $54.54 | 2022-2023 | Vonjo |
| Iovance Biotherapeutics, INC. | $54.41 | 2025 | Amtagvi |
| Agios Pharmaceuticals, INC. | $52.78 | 2023-2025 | Pyrukynd |
| Boston Scientific Corporation | $52.35 | 2023 | Therasphere Y90 Glass Microspheres 10 Gbq |
| Janssen Pharmaceuticals, INC | $47.01 | 2022 | |
| Jazz Pharmaceuticals INC. | $46.38 | 2024 | |
| Morphosys, US INC. | $44.20 | 2022-2023 | Monjuvi |
| Accord Healthcare, INC. | $43.05 | 2024-2025 | |
| Coherus Oncology, INC. | $42.65 | 2024-2025 | Loqtorzi |
| Pharmacosmos Therapeutics INC. | $42.40 | 2024 | Monoferric |
| Alnylam Pharmaceuticals INC. | $42.20 | 2022 | |
| Acrotech Biopharma INC. | $41.78 | 2022 | |
| Menarini Silicon Biosystems, INC. | $39.77 | 2024-2025 | |
| Mallinckrodt Hospital Products INC. | $32.46 | 2022 | |
| Fennec Pharmaceuticals, INC. | $28.32 | 2024-2025 | Fyarro, Pedmark |
| Emmaus Medical, INC. | $27.01 | 2023-2024 | Endari |
| Tactile Systems Technology INC | $26.50 | 2024 | Flexitouch Plus, Entre Plus |
| Csl Behring | $26.18 | 2021 | |
| Recordati_rare_diseases_inc. | $24.95 | 2023 | Sylvant |
| Caris Mpi, INC. | $24.59 | 2025 | Mi Cancer Seek |
| Servier Pharmaceuticals LLC | $23.82 | 2022 | |
| Legend Biotech USA INC. | $23.17 | 2025 | Carvykti |
| Ge Healthcare | $22.31 | 2021 | |
| Sirtex Medical INC | $22.14 | 2024 | Sir-Spheres Microspheres |
| Organon LLC | $21.34 | 2022 | |
| Progenics Pharmaceuticals, INC. | $20.87 | 2023 | Pylarify |
| Springworks Therapeutics, INC. | $20.68 | 2024 | Ogsiveo |
| Adc Therapeutics America, INC. | $20.18 | 2022 | |
| Myovant Sciences INC. | $17.52 | 2022 | |
| Sun Pharmaceutical Industries INC. | $17.37 | 2025 | |
| Immunocore Limited | $17.26 | 2024 | Kimmtrak |
| Telix Pharmaceuticals | $13.80 | 2023 | Illuccix |
| Cumberland Pharmaceuticals, INC. | $13.51 | 2024 | Sancuso |
| Clovis Oncology, INC. | $0.51 | 2019 |
Drugs and devices associated with these payments
Libtayo $878Kisqali $824Imbruvica $817Imfinzi $672Opdivo $634Lenvima $547Keytruda $531Sarclisa $523Ultomiris $474Reblozyl $437Krazati $426Jakafi $402Darzalex $392Talvey $391Tecvayli $391Elrexfio $378Trodelvy $375Lynparza $357Enhertu $346Xpovio $318Ninlaro $288Epkinly $268Scemblix $249Monjuvi $245Adcetris $225Ibrance $222Welireg $201Padcev $200Lorbrena $196Brukinsa $194Erleada $186Carvykti $183Rybrevant $179Braftovi $171Mektovi $171Tukysa $168Besremi $166Opdualag $158Tavalisse $150Rezlidhia $150Mekinist $146Piqray $142Nubeqa $139Cabometyx $136Doptelet $133Orgovyx $132Venclexta $127Fabhalta $125Tazverik $123Oxbryta $120Datroway $120Xalkori $112Ayvakit $106Pomalyst $103Provenge $97.18Yescarta $96.35Polivy $92.83Fotivda $91.40Xospata $86.37Qinlock $85.95Alunbrig $81.27Inqovi $80.96Lonsurf $80.96Orserdu $75.30Stivarga $72.62Vitrakvi $72.62Jaypirca $68.90Bosulif $68.89Tabrecta $65.64Fruzaqla $60.19Vonjo $58.32Clonoseq $56.63Amtagvi $54.41Tevimbra $53.05Pyrukynd $52.78Therasphere Y90 Glass Microspheres 10 Gbq $52.35Lutathera $51.39Somatuline Depot $49.61Onivyde $49.61Lunsumio $48.07Vyloy $47.92Xtandi $47.60Zepzelca $46.38Calquence $45.80Pluvicto $45.38Camcevi $43.05Monoferric $42.40Optune $41.74Cellsearch $39.77Xermelo $39.45Onureg $38.08Ojjaara $37.49Retevmo $36.58Tivdak $36.31Iclusig $32.83Xofigo $32.54Verzenio $32.32Keytruda Qlex $31.64Breyanzi $30.36Gilotrif $30.15
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Marjon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.